ArTara Therapeutics (TARA)

Overall impact
B (72)

Commentary

ArTara Therapeutics is a strong overall performer. With a 'B' rating of 72.1 for overall impact (85th percentile compared to all companies), ArTara Therapeutics ranks 219th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 215 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 363 others. On top material causes for ArTara Therapeutics's industry (Pharmaceuticals & Biotech), ArTara Therapeutics performs well in Reduced Use of tobacco (80.5 score), Child and Maternal Health (95.0), Improved Mental Health (91.5) and 4 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (35.3 score).
Impact
Cause TARA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2006
Employees
46
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
TARA
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for ArTara Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.